Karin Jooss
Net worth: 23 340 $ as of 2026-09-29
Net worth: 23 340 $ as of 2026-09-29
Karin Jooss is currently an Independent Director at Fate Therapeutics, Inc. since 2019.
Former positions include Executive VP & Head-Research & Development at Nexoplex Bio, Inc. from 2021 to 2024, Head-Cancer Immunotherapeutics at Pfizer Inc. from 2009 to 2016, and Vice President-Research at Cell Genesys, Inc. from 2005 to 2009.
Education includes a doctorate from Philipps University of Marburg.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-11 | 9,848 ( 0.01% ) | 23 340 $ | 2026-09-29 |
| Companies | Position | Start |
|---|---|---|
| FATE THERAPEUTICS, INC. | Director/Board Member | 2019-03-13 |
| Companies | Position | End |
|---|---|---|
| GRITSTONE BIO, INC. | Chief Tech/Sci/R&D Officer | 2024-12-30 |
| PFIZER INC. | Corporate Officer/Principal | 2016-03-31 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Chief Tech/Sci/R&D Officer | 2009-03-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Develops human disease therapies based on innovative gene modification technologies | Health Technology |
Pfizer Inc.
Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Philipps University of Marburg
Philipps University of Marburg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fate Therapeutics, Inc.
Fate Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Gritstone bio, Inc.
Gritstone bio, Inc. Pharmaceuticals: MajorHealth Technology Develops immunotherapies for cancer | Health Technology |
Select your edition
All financial news and data tailored to specific country editions